All In Biotech

Drug Trial Radar · NCT04978298

Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants

A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Effect of Ozanimod on Pressor Response to Oral Tyramine in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

128

Actual

Start

Jul 19, 2021

Primary completion

Feb 26, 2023

Study completion Feb 26, 2023

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, randomized, double-blind, placebo-controlled, active-controlled, comparator controlled, multi-dose, parallel-group study divided into three treatment periods and a follow-up period with five treatment groups. This study will be conducted at 1 clinical research unit (CRU) in the United States (US). Period 1 will consist of daily escalating doses of tyramine administered until tyramine pressor response (defined as the tyramine dose required to increase systolic blood pressure by at least 30 mm Hg from the daily defined baseline in 3 consecutive measurements within 4 hours after tyramine dosing) is achieved or Day 7. Participants who achieve tyramine pressor response at tyramine doses \>/= 200mg and \</= 700mg are eligible for continuation into Period 2 and will be randomized accordingly. Depending on the group to which a participant is randomized, participants will receive rasagiline, phenelzine, ozanimod (therapeutic dose), ozanimod (supra-therapeutic dose), or placebo in Period 2. The duration of dosing depends on the group to which a participant is randomized. In Period 3, all participants will undergo a sham tyramine challenge and receive a single dose of tyramine placebo. Participants who do not achieve tyramine pressor response following the sham challenge will continue with the tyramine challenge (ie, tyramine pressor tests) for up to 12 additional days. Participants who receive at least one dose of study drug in Period 2 will participate in a follow-up phase during which 2 follow-up telephone calls will be performed, the last of which will occur approximately 80 to 100 days after the last dose of study drug.

Conditions

  • Healthy Volunteers

Interventions

  • PlaceboOther

    Placebo

  • RasigilineDrug

    Rasigiline

  • PhenelzineDrug

    Phenelzine

  • OzanimodDrug

    Ozanimod

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tyramine Sensitivity Factor (TSF)Time frame: Up to Day 85

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Local Institution - 001

    Anaheim, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.